SCHEMBL1756237

SCHEMBL1756237

COC(=O)C(NC(=O)c1ncc(-c2ccc(NC(=O)Nc3ccc(Cl)cc3F)cc2)o1)C(C)C

nearest known ligand 0.56

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
CSGALNACT1 Q8TDX6 8/20 0.56
DGAT1 O75907 6/20 0.46
ALDH1A1 P00352 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.42
MEN1 O00255 1/20 0.42
MAPT P10636 1/20 0.42
HTT P42858 1/20 0.42
KMT2A Q03164 1/20 0.42
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA9 Q16790 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1756289 1.00 CSGALNACT1 (0.56) CSGALNACT1DGAT1ALDH1A1NPSR1SMN1; SMN2
SCHEMBL1756238 0.92 CSGALNACT1 (0.67) CSGALNACT1DGAT1
SCHEMBL1756240 0.92 CSGALNACT1 (0.67) CSGALNACT1DGAT1
SCHEMBL1756286 0.86 CSGALNACT1 (0.54) CSGALNACT1DGAT1NPSR1SMN1; SMN2MEN1
SCHEMBL1756284 0.86 CSGALNACT1 (0.54) CSGALNACT1DGAT1NPSR1SMN1; SMN2MEN1
SCHEMBL1756209 0.86 DGAT1 (0.64) CSGALNACT1DGAT1ALDH1A1NPSR1
SCHEMBL1756275 0.85 DGAT1 (0.44) CSGALNACT1DGAT1ALDH1A1NPSR1SMN1; SMN2
SCHEMBL1756274 0.85 DGAT1 (0.44) CSGALNACT1DGAT1ALDH1A1NPSR1SMN1; SMN2
SCHEMBL1756217 0.84 DGAT1 (0.56) CSGALNACT1DGAT1ALDH1A1NPSR1SMN1; SMN2
SCHEMBL1756319 0.83 DGAT1 (0.64) CSGALNACT1DGAT1ALDH1A1NPSR1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722901-B2 Carboxy oxazole or thiazole compounds as DGAT-1 inhibitors useful for the treatment of obesity Piramal Enterprises Limited (IN) 2014-05-13 US claimed
EP-2496564-A2 HETEROARYL COMPOUNDS AS DGAT-1 INHIBITORS Piramal Life Sciences Limited (IN) 2012-09-12 EP claimed
US-20120214854-A1 CARBOXY OXAZOLE OR THIAZOLE COMPOUNDS AS DGAT- 1 INHIBITORS USEFUL FOR THE TREATMENT OF OBESITY Piramal Enterprises Limited (IN) 2012-08-23 US claimed
WO-2011055289-A2 HETEROARYL COMPOUNDS AS DGAT-1 INHIBITORS PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-05-12 WO claimed
US-8722901-B2 Carboxy oxazole or thiazole compounds as DGAT-1 inhibitors useful for the treatment of obesity Piramal Enterprises Limited (IN) 2014-05-13 US disclosed
EP-2496564-A2 HETEROARYL COMPOUNDS AS DGAT-1 INHIBITORS Piramal Life Sciences Limited (IN) 2012-09-12 EP disclosed
US-20120214854-A1 CARBOXY OXAZOLE OR THIAZOLE COMPOUNDS AS DGAT- 1 INHIBITORS USEFUL FOR THE TREATMENT OF OBESITY Piramal Enterprises Limited (IN) 2012-08-23 US disclosed
WO-2011055289-A2 HETEROARYL COMPOUNDS AS DGAT-1 INHIBITORS PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120214854-A1 CARBOXY OXAZOLE OR THIAZOLE COMPOUNDS AS DGAT- 1 INHIBITORS USEFUL FOR THE TREATMENT OF OBESITY DGAT1, DGAT2, DLAT CSGALNACT1 555/4885DGAT1 1/4885ALDH1A1 592/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.